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ABSTRACT 
This thesis evaluates the safety and efficacy of cryoablation in supraventricular 
tachyarrhythmias. 
 
In Study I, the acute and long-term outcome of cryoablation therapy of typical 
atrioventricular nodal reentrant tachycardia (AVNRT) was studied in a large series of 
patients (n=312). Acute procedural success in AVNRT with cryoablation was achieved 
in 99% of patients with a recurrence rate of 5.8% during a mean follow-up period of 
22 months, which is similar to the expected outcome after radiofrequency ablation 
(RF). There were no long-term complications related to the use of cryoablation. 
Additionally, it was shown that further reduction of the recurrence rate may be 
achieved by using the endpoint of complete slow pathway elimination compared with 
residual slow pathway conduction. 
 
In Study II the clinical usefulness of cryoenergy for the ablation of perinodal 
atrioventricular reentrant tachycardia (AVRT) was investigated. Cryomapping of 
substrates adjacent to the AV-node may improve safety of the procedure. Acute 
procedural success with cryoablation in superoparaseptal and septal accessory 
pathways was achieved in 96% of the patients with a recurrence rate of 27% during a 
median follow-up of 33 months. The total success rate was 89% after a second 
cryoablation. Thus, acute and long-term results were similar to those reported for RF 
but without any complications related to the conducting system. 
 
In Study III the safety and efficacy of cryoablation of atrial tachycardia (AT) with high 
risk of ablation-related injuries was evaluated. AT foci originated from the para-hisian 
area, the vicinity of the sinus node, and the crista terminalis adjacent to the phrenic 
nerve were studied. Acute procedural success was achieved in 96% of patients with a 
recurrence rate of 12% during a mean follow-up period of 16 months. The total 
success rate after a second cryoablation was 92%, which is similar to that reported for 
RF ablation but without any permanent complications. 
 
 In Study IV cryoablation was compared to RF ablation for the treatment of  
cavotricuspid isthmus-dependent atrial flutter with emphasis on clinical success, safety, 
and procedure-related pain. The acute ablation success was 95% in the RF group and 
92% in the cryoablation group (NS). The long-term success after six-month of follow-
up was 92% for RF and 86% for cryoablation (NS). RF ablation caused significantly 
more pain compared to cryoablation both in terms of average and peak pain perception. 
 
 In conclusion, cryoablation of AVNRT, of high risk AVRT, and of AT are safe and 
effective alternatives to RF ablation without causing any permanent complication 
related to the conducting system and the phrenic nerve. Moreover, cryoablation of 
isthmus-dependent atrial flutter is not inferior to RF but with less procedure-related 
pain. 
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INTRODUCTION 
 
Radiofrequency (RF) ablation has become a standard form of therapy for most cases of 
supraventricular tachycardias [1-4], atrial flutter [5-6], atrial fibrillation [7-8], and 
ventricular tachycardia (VT) [9-10]. Although RF ablation has been proven to be highly 
effective, RF has several limitations as an energy source. For example, because the 
tissue destruction caused by RF energy is permanent, all clinical effects created by RF 
are essentially irreversible [11]. This translates into the inability with RF ablation to test 
the clinical effect of a lesion, which has important implications for ablation in close 
proximity to critical structures such as the atrioventricular (AV) node. RF energy is also 
associated with an increased risk of tissue charring and thrombus formation with 
potential for systemic embolization [12-14] in particular in association with ablation of 
large surface areas in patients with  atrial fibrillation (AF) or left ventricular tachycardia 
[12,14]. Additionally, the ability to create effective lesions with RF energy requires 
adequate catheter tissue contact as well as catheter stability. Furthermore, the use of RF 
energy within or around vascular structures may lead to complications such as coronary 
sinus injury or spasm [15], coronary sinus thrombus and adherence of RF catheter to 
the coronary sinus wall [16-17], coronary artery stenosis and thrombosis [16-17], and 
pulmonary vein stenosis [18-19]. 
   As a result of these limitations, the use of cryothermal energy has recently gained 
increasing attention as an alternative energy source for the ablation of cardiac 
arrhythmias. In fact, cryothermal energy offers several potential advantages over RF 
energy including improved catheter stability during lesion formation [20-21], potential 
for assessment of lesion effect before delivery of irreversible lesions, also known as 
cryomapping [22-23], decreased thrombogenecity [20, 24-25], safety within or near 
vascular structures [26-27] and significantly decreased levels of perceived pain by 
patients [68]. Despite this, systematic research into the clinical application of 
cryoablation has been scarce. Therefore, the present thesis was designed to assess the 
safety and efficacy of cryoablation in the treatment of selected supraventricular 
tachycardias. 
 
History of cryothermal energy  
Cold has been used clinically for thousands of years for its anesthetic and anti-
inflammatory effects. The earliest known mention of cold as remedy comes from 
Imhotep during the third Egyptian dynasty around 2600 BC. Imhotep is considered by 
many to have been the first published physician and perhaps the only physician to 
achieve official status as a god. Writings attributed to Imhotep were discovered on 
papyrus that was purchased in Luxor by Egyptologist Edwin Smith in 1862 (Figure 1). 
   The papyrus contains the description of 48 battlefield injuries and mentions the 
concept of cold compresses. The beneficial effects of cold in these cases reflect its 
utility as an anesthetic and anti-inflammatory agent.   
   The earliest descriptions in modern time of the use of cryothermal energy, in which 
carbon dioxide was used for the creation of transmural cardiac lesions, were provided 
by Hass and Taylor in 1948 [28]. They demonstrated the ability of hypothermia to 
produce a homogeneous, sharply demarcated lesion. Of particular interest was the 
resumption of normal function by epicardial vessels within minutes after removal of the 
freezing instrument from the epicardium. They also noted the ability to produce 
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transmural lesions in any cardiac chamber, without danger of rupture, aneurysmal 
dilation or intracardiac thrombosis [28-29] (Table 1). 
 
 
 
Figure 1.  Part of the Edwin Smith papyrus. 
 
 
   In 1964, Lister and Hoffman described reversible conduction block in the AV node 
after rewarming of a cryothermal energy lesion, which is currently referred to as 
cryomapping [30]. Since then, numerous groups of investigators have developed 
cryothermal technology, from an experimental energy source for the creation of 
intracardiac lesions in animals to a modern alternative energy source in humans  [20, 24, 
31-32].                                          
   Cryosurgery has been an integral part of the surgical management of cardiac 
arrhythmias since the late 1970s [33]. Before cryothermal systems were available, 
surgical ablation consisted primarily of surgical resection [34]. Some of the early 
reports of modern cryothermal mapping were provided by the cardiac surgical 
experience with cryothermal energy [35]. Intraoperative cryoablation has been shown to 
be safe and effective and has been successfully used in humans to map or ablate the AV 
node [31], accessory pathways [36], AV nodal re-entrant tachycardia (AVNRT) [37], 
atrial flutter [38], and VT (in combination with subendocardial resection) [39-41].  
   In 1980, Camm et al. described the ability to create reversible partial and complete 
conduction block in the AV node by placing a cryothermal energy probe in the His 
bundle position and cooling the tissue to between 0°C and -10° C [35]. They were able 
to demonstrate AH prolongation followed by complete dissociation, which completely 
resolved on rewarming. In 1998 Dubuc and co-workers demonstrated the feasibility of 
creating reversible cryothermal energy lesions by a transvenous steerable electrode 
catheter in dogs [20]. In 1999, Khairy et al. published early clinical experiences of 
percutaneuos transvenous catheter cryoablation in humans [32]. Recently, further 
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technical advancement of transvenous cryoblation has made it possible for invasive 
cardiac electrophysiologists to treat a broad range of cardiac arrhythmias [23, 32, 42]. 
 
 
Table 1. Historical landmarks in transvenous cardiac cryoablation 
 
Year Authors Contribution 
1948 Hass &Taylor Used cryothermal energy for the creation of transmural cardiac 
lesions 
1963 Cooper Developed first cryosurgical apparatus  
1964 Lister & Hoffman Described reversible conduction block by cryothermal energy 
1977 Harrison et al Performed cardiac cryosurgery with a hand-held probe 
1991 Gillette et al Conducted an animal study with a transvenous cryocatheter 
1998 Dubuc et al Used of steerable cryocatheter system with pacing and recording 
electrodes 
1999 Khairy et al Used percutanous transvenous cryocatheter ablation in humans 
 
Biophysics of cryothermal energy  
The application of cryothermal energy to cardiac tissue results in the formation of a 
well-demarcated hemispherical block of frozen tissue, an ice ball [33]. The tissue goes 
through a series of stages before forming into a stable lesion. The main stages in the 
creation of a cryothermal energy lesion include the following: (1) freeze/thaw phase, 
(2) hemorrhage and inflammatory phase, and (3) replacement fibrosis phase [33,43-45]. 
Therefore, the lesions created by cryothermal energy sources are morphologically 
different in the acute and chronic phases. 
 
Freeze/thaw phase 
This phase results in the initial changes associated with direct cryothermal lesion 
application that occurs within the first hours after delivery. In this stage, freezing results 
in the formation of intracellular and extracellular ice crystals. The ice crystals do not 
penetrate cellular membranes; rather they cause compression and distortion of 
intracellular organelles. More importantly, extracellular ice crystal formation removes 
extracellular free water and causes intracellular desiccation. Furthermore, because of 
the withdrawal of water caused by freezing, the remaining water becomes 
hyperosmotic, and concentrations of electrolytes become elevated intracellularly, 
contributing to cell death. Once thawing begins, first in the extracellular matrix, the 
hypotonic fluid moves back into the cells, causing the cells to swell and cell 
membranes to rupture. The thawing of ice crystals also results in increased membrane 
permeability in mitochondria and disruption of intracellular transport mechanisms. 
Once these changes occur, irreversible cell death takes place. 
 
Hemorrhage and inflammatory phase  
The second stage of myocardial damage consequent to cryotherapy is characterized by 
the development of hemorrhage, edema and inflammation (coagulation necrosis), 
which are evident within 48 hours after thaw. By one week after the thaw, the now 
inflammatory lesions have become sharply demarcated by macrophages, lymphocytes, 
and fibroblasts and collagen stranding has begun. 
 
Replacement fibrosis phase  
The third and final phase in the evolution of a cryothermal energy lesion is the 
replacement fibrosis phase. A number of weeks after ablation, the myocardial tissue 
within the lesion are become replaced by dense collagen and fat. A short while 
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afterwards, the lesion is densely fibrotic, and up to three months later it has decreased 
to its final size. 
 
Differences between Cryo and RF  
The characteristics of lesions created by cryothermal energy differ from those created 
by RF energy and have been well described by a number of investigators [20-21, 46]. 
Unlike heat that destroys cells by coagulation and tissue necrosis with potential for 
thrombus formation and aneurysmal dilation, cryothermal energy involves a distinct 
pathophysiologic process. Lesions created by a 4-minute cryoablation application at 
temperatures lower than –50º C are grossly hemispherical in shape with a sharply 
defined interface with normal myocardium and well-preserved architecture (Figure 2).     
Because they are not associated with any significant endothelial damage, they are also 
typically free of surface thrombosis [25]. 
   These findings are in contrast to lesions created by RF, which are less sharply 
demarcated and have an architecture that is not as well-preserved. In addition, these 
lesions may be associated with surface endothelial disruption and therefore are more 
likely to be associated with surface thrombosis [47-48]. Khairy et al. demonstrated that 
RF ablation resulted in lesions of greater area (RF in median 42.0 mm² vs. Cryo 20 
mm²; P=0.002) and nearly significantly larger volume (RF in median 94.6 mm³ vs 
Cryo 43.2 mm³; P=0.06) but not depth compared with cryolesions (RF mean 6 mm vs 
Cryo 4.9 mm; P= NS) [25]. Colder temperatures, however, were though associated 
with deeper lesions. For example, achieving a peak temperature 10°C colder resulted 
in an average lesion 0.38 mm deeper (P=0.0001) [25]. 
   Since a RF lesion is created with the beating heart moving in contact with the 
catheter, the lesion is delivered over an area slightly larger than the catheter tip as the 
result of a “brushing” effect. As the cryoablation catheter is frozen to the tissue during 
cryoablation, this allows the delivery of a focused lesion without a similar “brushing” 
effect [20-21], and without the possibility to adjust or move the catheter during lesion 
formation. Thus, cryoadhesion provides stable contact, eliminates cathter movement 
during ablation and results in stable delivery of cooling into the target area, potentially 
limiting the risk of collateral damage. In addition, this feature permits programmed 
stimulation during an application and no further fluoroscopy is needed when 
cryoadhesion occurs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cryo RF 
Figure 2. Schematic diagram comparing lesion architecture between a 
cryoablation lesion (right) and a RF lesion (left); reproduced with 
permission from reference 25. 
 
Minimal thrombus     Endocardium intact    Disrupted endocardium    Thrombus 
Fibrosis complete    Well demarcated               Haemorrhage present              Fibrosis 
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Cryomapping (ice-mapping) and cryoablation   
Once the ablation target is identified, the operator can choose between two modes of 
operation. Typically, a cryomapping application is performed first and is used to assess 
the electrophysiological effect of the application. This allows the operator to cool the 
target tissue to approximately -30° C. Should the operator note an undesired effect of 
the cryomapping lesion such as prolongation of  the AH interval or complete AV block, 
the cryomapping can be terminated, with complete recovery of conduction within 
seconds after rewarming and without any risk for permanent damage. Hence, the 
cryomapping procedure can be repeated as many times as the operator chooses until a 
favourable position is reached and the cryoablation mode is started. During 
cryoablation mode, the temperature is further decreased to below - 75° C for up to four 
minutes, resulting in a permanent lesion. Should the operator note an undesirable 
electrophysiologic effect during cryoablation, the cryoapplication can be terminated. If 
it is terminated immediately upon the appearance of the unwanted effect conduction 
typically returns to normal on rewarming with no residual conduction abnormality.   
 
Components of a cryoablation system  
The cryoablation system consists of a steerable catheter controlled by a microprocessor-
based electromechanical refrigeration console. Catheters and console are used together 
to deliver fluid refrigerant from a storage tank inside the console to the catheter tip and, 
in accordance with the principles of heat extraction, remove vaporized refrigerant by 
evacuation through a scavenging hose. These devices all rely on the Joule-Thomson 
effect, whereby a refrigerant at high pressure, for example, liquid N2O, flows down the 
central lumen of an injection tube and then evaporates at the tip of the catheter into the 
outer shaft at lower pressure, causing cooling of the catheter tip. 
 
Catheters  
Cryoablation catheters achieve tissue freezing by delivery of a refrigerant (typically  
N2O) through an infusion channel to an evaporation chamber in a thermally-conductive 
tip electrode resulting in marked heat removal from the catheter tip and contiguous 
tissue. Another channel is under vacuum for evacuation of the expanded nitrogen gas 
(Figure 3). By removing heat from tissue, cryothermal systems achieve the cooling and 
freezing of the tissue to affect cellular function and activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Schematic figure demonstrating the CryoCath Freezor cryocatheter internal 
design. The cryocatheter is a lumen catheter containing passageways for the delivery of 
liquid refrigerant and removal of refrigerant in vapor form. A thermocouple, for temperature 
sensing, is embedded in the tip of the catheter and ECG wire for ECG signal. Reproduced 
with permission of Medtronic, Inc. 
ECG wire           Deflection wire       Refrigerant 
Vacuum return lumen   Injection tube    Thermocouple wire       
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Cryo console   
The console allows the operator two modes of operation. The first is Cryomapping 
mode, in which the tip is cooled to a temperature of - 30º C for up to 60 seconds. 
Cryomapping allows the delivery of an application with reversible effect. The second 
mode is the Cryoablation mode, which cools the electrode tip to -75º C for usually four 
minutes, resulting to permanent lesion. Cryoablation may be initiated at any time 
during a cryomapping application or without any prior cryomapping. The cryoablation 
system is depicted in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Cryoablation system consisting of a steerable catheter, console and connectors. The 
cryocatheter and console are connected by a coaxial tube that delivers fluid nitrous oxide (N2O) 
to the catheter and removes refrigerant vapor from the catheter. The coaxial tube also shields 
the liquid refrigerant from the warming effects of ambient air in the electrophysiology (EP) 
laboratory. The gas removed from the catheter to the console is evacuated through a 
scavenging hose into the scavenging line of the EP laboratory. Reproduced with permission of 
Medtronic, Inc. 
 
 
Technical aspects    
The efficacy of a cryoablation system depends on two important phenomena: heat 
pump capacity and heat transfer efficiency. The heat pump capacity is related to the 
amount of heat the refrigeration system can remove, and how much of that heat comes 
from the ablation site is correlated to the heat transfer efficiency. 
 
Heat pump capacity 
Temperature control and refrigerant-flow control are important parameters to determine 
the efficacy of cryoablation systems [133]. During a cryoablation procedure, 
pressurized refrigerant is delivered to the catheter tip to achieve and sustain a 
predefined ablation temperature or flow. This continuous temperature/flow control 
compensates for heat-load changes due to blood circulation during a cardiac cycle or 
adjustments in tip-tissue interface. The cryoablation console includes algorithms that 
control refrigerant delivery to maintain a preset temperature value (mode) or flow value 
(mode). In temperature mode, the catheter-tip temperature largely depends on tip 
orientation in relation to the tissue (Figure 5). If the catheter tip is held parallel to the 
tissue, the temperature sensor will be positioned in the bloodstream. As a result, the 
sensor will read a warm temperature, prompting the system to deliver more refrigerant 
to the tip to achieve the predefined temperature value. If the catheter tip is held 
Autoconnection 
box  
ECG cable 
Sterile coaxial 
umbilical 
 
Sterile electrical 
umbilical 
  
Cryoconsole 
 
Scavenging hose  
Cryoablation 
catheter 
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perpendicular to the tissue, the temperature sensor will be positioned at the tip-tissue 
interface. A relatively small amount of refrigerant at the catheter tip will provide a cold-
temperature reading because the tip temperature is not influenced by blood flow.  
   The perpendicular position will generate a colder temperature than the parallel 
position, but cooling performance in the parallel position is much greater than in the 
perpendicular position, even if the temperature reading indicates the opposite. The 
advantage of temperature mode is that it remains sensitive to the heat-load environment 
[133]. In flow mode, the catheter tip is flooded with a predefined volume of refrigerant, 
providing consistent cooling power independently of tip temperature or position. In 
flow mode, the system does not recognize the difference between high or low heat 
loads; instead, it provides a constant flow of refrigerant and is normally limited by flow 
capacity in the catheter. 
 
Heat transfer efficiency  
The nature and extent of the contact between the cooled catheter tip and the tissue are 
as important to the efficacy of cryoablation as the cooling capacity of the system. The 
catheter tip must be designed for high thermal conductivity and biocompatibility for use 
in the bloodstream [133]. 
 
 
 
 
Figure 5. The catheter tip parallel to the tissue produces a larger lesion compared to 
perpendicular position. Reproduced with permission of Medtronic, Inc. 
 
 
Important Factors for cryoablation efficacy  
Cryoablation efficacy is defined as the tissue temperature and lesion size that must be 
achieved to stop an arrhythmia from recurring.  Several parameters have been shown to 
be important for cryolesion formation and morphologic characteristics of cryolesions. 
 
Effects of Blood Flow   
While the endocardial applications require high cooling power (high refrigerant flow) 
to offset the heat load of flowing blood, epicardial applications require less cooling 
power due to the absence of blood flow at the tip of the catheter. Low-flow areas result 
in larger and deeper cryolesion formation [74]. Therefore, cryoablation has an 
advantage in trabeculated areas, also ablating inside of the low-flow “pouch” during 
typical isthmus ablation. 
 
  B 
B 
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Freezing Duration  
Cryo application time is clinically an extremely important issue. A duration of four 
minutes typically is required, because lesion size continues to expand during the 
cryoablation application, up to a duration of two to three minutes (Figure 6). Therefore, 
applications shorter than four minutes may not result in complete lesion delivery. 
 
 
 
 
Figure 6: Schematic diagram shows that as the catheter tip is cooled, the adjacent cardiac 
tissue is also cooled. The longer the catheter is cooled, the larger the ice ball formation and the 
larger the lesion created, with an upper limit of approximately two to three minutes of 
application when cooling to –75 ºC. The lowest temperature and fastest freezing rate are 
generated at the point of contact (distal catheter tip). Slower cooling rates are obtained for 
tissue peripheral to the contact point. Reproduced with permission of Medtronic, Inc. 
 
 
Double Freezing (freeze/thaw/freeze)  
Double freezing results in a deeper and larger lesion because of repeated freeze/thaw 
effects on cell membranes [75]. 
 
Contact Pressure  
Increased pressure results in faster freezing, because of compression of the tissue and 
decreased warming effects of intra-myocardial flow [76]. 
 
Catheter Size 
Larger catheter size results in larger lesions since the catheter tip in contact with 
myocardium is “protecting” that area from direct blood flow washout effects and 
additionally larger catheter size can incorporate larger diameter channels, supplying 
more refrigerant and, therefore, increasing freezing power [77]. A relatively large 
catheter tip at -50ºC can produce a larger lesion than a relatively small catheter tip at - 
75 ºC. There is a direct correlation between tip size and the volume of refrigerant that is 
delivered to the target site (Figure 7). 
 
Refrigerant 
Another important factor is the quality of refrigerant, which clearly affects heat transfer 
in cryoablation procedures. Refrigerant that is delivered to the cooling chamber in a 
liquid state exchanges more heat than refrigerant in a gaseous state.  Only nitrous 
oxide-based cryocatheters (-80°C) are available for transvenous catheter ablation. Other 
coolants are available in surgical probes with much lower boiling temperatures and are 
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more effective. The most widely used coolant in surgical settings is liquid nitrogen 
(N2), which boils at (-196°C). Argon gas-based (boiling point at = -160°C) cryosurgical 
devices are also available.   
 
 
 
  
 
Figure 7. Larger tip sizes produce greater lesions because more refrigerant is delivered  to the 
tissue. Reproduced with permission of Medtronic, Inc. 
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AIMS OF THE THESIS 
 
 
The overall objective of this research work has been to study the safety and efficacy of 
cryoablation in supraventricular tachyarrhythmias. Specific aims are outlined below. 
 
 
Study I. 
 
To study the acute and long-term outcome of cryoablation therapy of typical 
atrioventricular nodal reentrant tachycardia (AVNRT) in a large series of patients. 
 
 
Study II. 
 
To investigate the clinical usefulness of cryomapping for ablation of perinodal 
accessory pathways and to evaluate the acute and long-term results of transvenous 
cryoablation of septal and superoparaseptal accessory pathways.   
 
 
Study III. 
 
To study the safety and efficacy of cryoablation of atrial tachycardia with high risk of 
ablation related injuries.  
 
 
Study IV. 
To compare cryoablation and radiofrequency ablation in the treatment of  CTI-
dependent atrial flutter with emphasis on clinical success, safety and procedure-related 
pain. 
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MATERIAL AND METHODS 
 
Patients  
Study I 
Between January 2003 and May 2007, all consecutive patients undergoing ablation of 
typical (slow–fast) AVNRT using cryothermal energy were included. During this 
period, 312 patients with typical AVNRT underwent cryoablation.   
 
Study II 
The study population consisted of all patients undergoing a first transvenous catheter 
ablation procedure of a superoparaseptal or septal AP using cryothermal energy 
between January 2004 and December 2008. During this five-year period, 464 patients 
underwent transvenous catheter ablation of AP at our institution. Twenty-seven (5.8%) 
of these patients had an AP located either in the superoparaseptal (n=18) or in the septal 
(n=9) region. 
 
Study III 
The study population consisted of all patients undergoing a first transvenous catheter 
ablation procedure for high-risk-located AT using cryothermal energy between May 
2004 and July 2007. During this period, 164 patients underwent transvenous catheter 
ablation of AT at our institution. Twenty-six of these patients were considered 
to have high-risk-located AT and constituted the study population. The AT foci 
distribution was as follows: close to the AV node (n=14); in the vicinity of the sinus 
node (n=7); and at the crista terminalis adjacent to the phrenic nerve (n=5). 
 
Data Collection (Studies I- III) 
Crucial demographic, clinical, and EP information was collected prospectively 
by the treating electrophysiologist at the time of the EP study and stored in an 
electronic database containing all consecutive EP studies at the Karolinska University 
Hospital (FileMaker Inc., Santa Clara, CA, USA). 
 
Study IV 
Between January 2007 and May 2010, all consecutive patients referred to our 
institution for ablation therapy of ECG-documented typical CTI-dependent AFL were 
considered for inclusion. Patients above the age of 18 were included if they had 
symptomatic CTI-dependent AFL documented on a 12-lead ECG with typical ECG 
appearance of negative saw tooth waves in the inferior limb leads and positive 
deflections in V1 or positive saw tooth waves in the inferior limb leads and negative 
deflections in V1. Patients with a history of atrial fibrillation were only included if they 
had predominant atrial flutter under chronic treatment with class I or III antiarrhythmic 
agents. Patients were excluded if they had  prior ablation for AFL, atrial flutter related 
to recently undergone surgery, hyperthyroidism or other severe disease, an inability to 
adhere with the study protocol, predominant atrial fibrillation, and contraindication to 
warfarin.   
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Data Collection and pre-ablation assessment (Study IV) 
Patients were assessed by medical history, physical examination and a standard 
transthoracic echocardiography. Routine laboratory tests were obtained within 72 
hours before the procedure. In all patients with persistent AFL warfarin was continued 
before ablation with a target INR between  2-3. Antiarrhythmic drugs were continued 
before and during the ablation. All data were collected, using standardized case report 
forms (CRF). In the electrophysiology laboratory, the operator opened a sealed, 
opaque envelope containing the randomization assignment. 
 
Data Collection and  post-ablation follow-up (Study IV) 
An ECG was taken within six hours after the procedure. Upon discharge, all patients 
were instructed to contact the study coordinators in case of any symptoms suggestive 
of arrhythmia recurrence. In this case, rhythm was assessed using a 12-lead ECG, 
Holter–monitoring or Event Recording (ER), depending on the symptoms. Patients 
also received a diary to note any symptoms of arrhythmia following the ablation.  
Relapse was defined as ECG documented CTI-dependent AFL. All patients were 
routinely seen after six months in the outpatient clinic. At this follow-up visit, a 
physical examination, an ECG recording, and a review of the patient diary were 
performed, and all patients were also intensively questioned about arrhythmia or 
other cardiac-related symptoms. A second ablation procedure, predetermined with RF 
energy, was scheduled for patients with a relapse of symptomatic and documented 
common AFL. 
 
Definitions (Studies II-III)  
Superoparaseptal AP 
Pathways were classified as superoparaseptal if an AP activation potential as well as a 
His bundle potential were simultaneously recorded from a mapping catheter placed at 
the His bundle region. At fluoroscopy, the tip of the mapping catheter was near the His-
catheter in different radiological views. 
 
Septal AP  
Pathways were classified as right septal if either the earliest anterograde ventricular 
activation or an AP potential was recorded from a catheter located in an area bounded 
superiorly by the tip electrode of the His bundle catheter and inferiorly by the CS 
ostium, excluding AVNRT and septal or parahissian ectopic atrial tachycardias. 
 
Atrial tachycardia near the atrioventricular node 
Atrial tachycardia originating near the AV node or the His bundle is characterized by 
the presence of His-bundle potential in the local electrogram or by fluoroscopic 
proximity of the ablation site to the His-bundle, excluding AVNRT and AVRT. 
 
Atrial tachycardia near the sinus node 
Atrial tachycardia originating from the SN complex is located at the superior aspect 
of the crista terminalis with identical or almost identical P wave and intracardiac 
activation sequence during tachycardia and sinus rhythm. 
 
Atrial tachycardia near the phrenic nerve 
Atrial tachycardia originating along the lateral right atrium and with high output (10 
mA) pacing resulted in phrenic nerve stimulation. 
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Ablation procedure (Studies I-III) 
Antiarrhythmic drug medication was discontinued five half-lives before the study. All 
procedures were performed under light sedation, under local anesthesia, and in the 
fasting state. Heparin was given routinely. A conventional EP study was performed 
with diagnostic catheters positioned in the right ventricle apex, in the coronary sinus, 
and in the His position. 
 
AVNRT (Study I)  
The diagnosis of typical AVNRT was confirmed. After standard EP assessment, an 8 
F 6-mm cryocatheter Freezor Extra (Medtronic Cryo-Cath, Minneapolis, MN USA) 
was positioned fluoroscopically across the tricuspid annulus starting just anterior and 
slightly inferior to the coronary sinus ostium. A local atrial electrogram with a 
terminal fractionated component and an A/V ratio of 1:3 or 1:4 was sought. A 
combination of electrogram analysis looking for slow pathway potentials and 
anatomical approach were used to identify appropriate target sites for ablation. 
Fluoroscopy with RAO 30º and LAO 60° projections was used. In case of inadequate 
catheter stability, a long sheath (SR0, St. Jude Medical, Sylmar, CA, USA) was used. 
In patients who had dual AV nodal physiology with a clear jump (more than 50 ms), 
echo beats, complete circles, or reproducibly inducible AVNRT at baseline, 
cryomapping was performed during atrial extrastimulus testing with a coupling 
interval critical for slow pathway conduction and/or AVNRT induction. If there was 
no clear jump and/or AVNRT was difficult to induce at baseline, the prolongation of 
the antegrade AV refractory period during atrial extrastimulus testing was used to 
identify the potential ablation sites.  
   At the location of interest, cryomapping at -30°C for a maximum of 20 s was 
performed. If there was a clear effect on the arrhythmia substrate such as non-
inducibility, loss of slow pathway conduction, or prolongation of refractory period 
within this time, cryoablation with a goal temperature of - 80°C for 240 s was 
applied. In case of no effect within 20 s or AV prolongation, cryomapping was 
stopped and then repeated at a new target site. Programmed stimulation was 
performed to test the effectiveness of the therapy during cryoablation. If AVNRT was 
still inducible or if AV prolongation or AV block occurred, cryoablation was 
terminated and cryomapping at new sites was done.  
   Both cryomapping and cryoablation were initiated during sinus rhythm. Following 
successful cryoablation, arrhythmia induction was attempted for 30 minutes to 
confirm the effectiveness of the slow pathway ablation using non-inducibility as 
endpoint. Jumps with or without single nodal echoes were accepted, but not complete 
circles (two or more nodal echo beats) after 30 minutes. Isoproterenol infusion was 
used during arrhythmia induction both before and after cryoablation when deemed 
appropriate. 
 
AP (Study II) 
A 12-lead surface ECG during pre-excitation was obtained and analyzed. The delta-
wave morphology was used to predict the site of origin. Both AV conduction and 
refractoriness in the anterograde and retrograde direction were evaluated by 
incremental atrial and ventricular pacing as well as by extrastimulus (ES) technique. 
Atrial single and double premature ES and incremental pacing were used to induce 
tachycardia. In addition, isoproterenol infusion was used when the tachycardia was not 
inducible at baseline.   
   After the standard electrophysiologic assessment, an 8 F 6-mm cryocatheter Freezor 
Extra was advanced to the area of interest. Subsequently, the arrhythmia substrate was 
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mapped by combining electrogram analysis and anatomical location with fluoroscopy. 
Biplane fluoroscopy (RAO 30° and LAO 60º) was used. In case of inadequate catheter 
stability, a long sheath (SR0, St. Jude Medical) was used.  
   In patients with pre-excitation, the localization of the AP was identified by careful 
mapping of the atrial and ventricular activation pattern using distal unipolar and bipolar 
electrograms, specifically the shortest AV interval, the earliest anterograde ventricular 
activation to surface delta wave during sinus rhythm, and “QS” morphology on 
unipolar leads.  
   In those with concealed AP, the earliest atrial activation during orthodromic 
tachycardia and/or sinus rhythm with intermittent ventricular pacing was used. At the 
location of interest, cryomapping at -30º for a maximum of 20 s was attempted 
followed by re-evaluation of the arrhythmic substrate or inducibility. If the patient had 
pre-excitation, cryomapping was done either during sinus rhythm or tachycardia, 
monitoring for a loss of delta wave or termination of the orthodromic tachycardia, 
respectively. In the case of concealed AP, cryomapping was done either during 
orthodromic tachycardia or intermittent ventricular pacing to terminate the tachycardia 
or to create retrograde block in the AP, respectively.  
   The cryoenergy was discontinued if no effect was achieved within the first 20 seconds 
of cryomapping. If there was a clear effect on the arrhythmia substrate, such as loss of 
delta wave, non-inducibility, or retrograde block of conduction through the AP, 
cryoablation with a goal temperature of -80ºC for 240 s was done. Programmed 
stimulation was performed to test the effectiveness of the therapy during cryoablation. 
AV conduction was closely monitored during cryomapping as well as during 
cryoablation. The ablation was immediately stopped if any sign of impairment of AV 
conduction or ineffective result was found. Following successful cryoablation, 
arrhythmia induction was attempted for 30 minutes to confirm the effectiveness of the 
ablation using non-inducibility and conduction block in the anterograde and retrograde 
direction in AP as endpoints. 
 
AT (Study III) 
A 12-lead surface ECG during AT was obtained and analyzed. The P-wave 
morphology was assessed to predict the site of tachycardia origin. After a 
conventional diagnostic EP study, the diagnosis of AT was confirmed. Isoproteronol 
infusion was used when the tachycardia was not inducible at baseline. An 8 F 6-mm 
cryocatheter Freezor Extra was advanced to the area of interest. The arrhythmia 
substrate was mapped by combining electrogram analysis and anatomical location. 
   A non-contact mapping system (Ensite, St Jude Medical) was used for mapping and 
ablation of AT near the SN (Figure 8). In cases with AT foci along the lateral right 
atrium, fluoroscopy was performed every 10 to15 s during cryoablation to observe the 
respiratory motion of the right hemidiaphragm and the ablation was stopped if an 
impairment was seen. At potential target sites, cryomapping at -30°C for a maximum 
of 20 s was performed. If AT became non-inducible or tachycardia terminated, 
cryoablation with a goal temperature of -80°C for four min was performed. The AV-
nodal conduction and sinus cycle length were continuously monitored during 
cryomapping and cryoablation. Procedural success was defined as non-inducibility 30 
minutes after the last cryoapplications. 
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Figure 8. Non-contact mapping in atrial tachycardia (AT) near the sinus node. (A) and (B) 
Sequence of early endocardial breakthrough during sinus rhythm at baseline, in an 
isopotential map. (C) An early breakout during AT, in a newly created isopotential map 
indicating the origin of the AT in the vicinity of the sinus node. SVC, superior vena cava; IVC, 
inferior vena cava; SN, sinus node; bo, breakout. 
 
 
Ablation procedure (Study IV)  
Patients underwent EP-study in the fasting state with a light sedation under local 
anesthesia. The standard fluoroscopy or a 3D non-fluoroscopic mapping system (Ensite 
NavX) was used. In the presence of atrial flutter a CTI-dependent re-entrant loop was 
verified by demonstration of concealed entrainment from the CTI and an activation 
pattern around the tricuspid annulus (TA) consistent with CTI-dependent AFL either 
using the ablation catheter or by a 7 F duodecapolar Halo catheter (Daig, St. Jude 
Medical, USA) positioned around the TA. In patients in sinus rhythm, stimulation at the 
CS-ostium and the infero-lateral part of the right atrium was performed  to demonstrate 
conduction through the CTI before ablation. 
    In patients randomized to the RF group, the procedure was performed using a 7 F 
3.5-mm tip open-irrigated catheter (Biosense-Webster, Inc. USA) to create an ablation 
line between the tricuspid valve and the inferior vena cava (IVC). Continuous RF 
energy was delivered with preset parameters of 30 to 40 Watts with a goal temperature 
of 40-42ºC and a cut-off limit of 48 ºC.  
   In the Cryo group, cryoablation was performed using a sequential application 
technique point-by-point from the TV annulus to the IVC. A steerable 9 F, 8-mm-tip 
cryocatheter Freezor Max (Medtronic Cryo-Cath) was used. Ablation was performed at 
a target temperature of –80 ºC. Each application lasted for 240 s. Acute ablation success 
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was defined as complete bidirectional conduction block (BCB) in the CTI persistent 30 
minutes after final energy delivery. 
   Pain was evaluated using a Visual Analogue Scale (VAS) ranging from 0 (“no pain at 
all) to 10 (“the worst possible pain”). The VAS score was determined before starting the 
application, during the application, and at the end of each application. 
 
Follow-up (Studies I-III)  
Clinical follow-up was based on outpatient visits, medical records, and telephone 
contacts. A 12-lead surface ECG was obtained in all patients at the long-term follow-
up. Holter monitoring or an EP study was done depending on the presented symptoms. 
In addition, a symptom questionnaire was sent to all patients. Patients were asked 
whether they were totally free from arrhythmia symptoms, significantly better, 
somewhat improved, or if the symptoms were unchanged or had deteriorated. They 
were also asked about the frequency of symptoms: daily, several times per week, once 
per week, or less. Furthermore, if they had experienced a recurrence of arrhythmia 
symptoms, they were asked to describe these symptoms. Finally, the patients were 
asked about current anti-arrhythmic drug therapy. If recurrence was suspected, the 
patient was subjected to further investigation. Recurrence was defined as ECG-
documented tachycardia, relapse of pre-excitation (delta-wave), or return of clinical 
symptoms identical to those before cryoablation. 
 
Follow-up (Study IV)  
An ECG was taken within six hours after the procedure. Upon discharge all patients 
were instructed to contact the study coordinators if any symptoms suggestive of 
arrhythmia recurred. In this case, rhythm was assessed using a 12 lead ECG, Holter–
monitoring, or Event Recording (ER), depending on the symptoms. Patients also 
received a diary to record any symptoms of arrhythmia following the ablation.  Relapse 
was defined as ECG documented CTI-dependent AFL. All patients were routinely seen 
after six months in the outpatient clinic. At this visit a physical examination, an ECG 
recording and, a review of the patient diary were performed. In addition, all patients 
were also intensively questioned about arrhythmia or other cardiac-related symptoms. 
 
Statistical analysis (Study I-III)  
Data are presented as median and range or mean±SD as appropriate. Continuous data 
were compared using Mann–Whitney U test or Student´s t-test. For categorical data, 
proportions were analyzed using the chi-square test. P<0.05 was considered 
significant. Statistical analyses were performed using commercially available 
software (Statistica, version 8.0, StatSoft Scandinavia AB). 
 
Statistical Analysis (Study IV)  
The primary analysis was designed to test the hypothesis that cryoablation was non-
inferior to RF with regard to success rate at the six-month follow-up with an upper 
margin of 10% difference between the groups. Power calculation was based on a 
predicted 95% success rate using RF ablation. Thus, 75 patients were required in each 
group to demonstrate non-inferiority of cryo with a statistical power of 80% (α = 0.05 
and ß = 0.2). The calculation is based on the following formula: N= [2π (1- π) / δ²] x 
7.9 or N=[2x0.95x0.05/0.01] x 7.9 = 75.05, where π = 0.95 (success rate for the 
standard method) and δ (pre-defined non-inferiority margin) = 0.1. 
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 Normally distributed data were expressed as mean ± SD, and non-normally distributed 
data are given as median and range. Continuous data were compared using Mann-
Whitney U test or Student´s t-test. For categorical data, proportions were analyzed 
using a chi-square test. Statistical analyses were performed using commercially 
available software. Event free survival rates were estimated with the Kaplan-Meier 
method. 
   For analysis of the learning curve for the participating electrophysiologists, a 
bootstrap regression was performed with 3000 replications, with replacement, drawn 
from the original sample. This was due to non-normal distributed procedure time. Each 
sample was set to have the same number of subjects drawn regarding each half of the 
learning time. The results from this analysis are presented as mean procedure time with 
95% bias corrected accelerated (BCa) confidence intervals. The Intercooled Stata 11.0 
statistical software (Stata Corp LP, College Station, TX, USA) was used for the 
bootstrap regression analysis. 
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RESULTS 
 
Study I 
Acute and long-term outcome of cryoablation therapy of 
typical atrioventricular nodal reentrant tachycardia 
 
Aim 
To study the acute and long-term outcome of cryoablation therapy of typical 
atrioventricular nodal reentrant tachycardia in a large series of patients. 
 
Results 
Efficacy 
Acute success was achieved in 309 of 312 patients (99%). Total procedure time was 
128±52 min (median 120 min) and fluoroscopy time was 18±14 min (median 20 
min). During a mean follow-up of 673±381 (median: 588 days), the overall 
recurrence rate was 18 of 309 (5.8%), giving a total success rate of 94.2% after a 
primary successful cryoablation. Of these 18 patients, 16(89%) were successfully re-
ablated. Thus, the total success rate after a second cryoablation session was 98%. 
 
Safety 
A total of 20 procedure-related episodes of transient second- or third-degree AV block 
occurred in 16 patients (5%) either during cryomapping (n=7) or during cryoablation 
(n =13). The AV conduction was restored within seconds after thawing. No permanent 
AV block was reported during the follow-up period of 672±380 (median: 588 days). 
   Two procedure-related complications occurred. One patient developed a small 
pneumothorax after catheterization of the subclavian vein and the other a 
pseudoaneurysm in the groin. Both patients were treated conservatively and 
recovered completely. 
 
Predictors of recurrence 
Recurrence was more likely in patients with transient procedure-related AV block 
(4/18, 22%) compared with those without transient AV block (12/294, 4%; P < 0.001). 
The recurrence rate in patients with residual dual AV nodal pathway post-ablation was 
9% (11/123) compared with 4% (7/189) in those with complete block of slow 
pathway conduction (P = 0.05). Furthermore, AVNRT recurrence was associated with 
a trend towards a longer procedure time (P = 0.058). 
 
Conclusion  
Cryoablation of AVNRT can be performed with a high acute success rate and a 
reasonable recurrence rate at long-term follow-up. Additionally, further reduction of 
the recurrence rate may be achieved with complete elimination of slow pathway as 
endpoint compared with residual slow pathway conduction. 
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Study II 
Cryoablation of superoparaseptal and septal accessory 
pathways: a single center experience 
 
Aim 
To investigate the clinical usefulness of cryomapping for ablation of perinodal 
accessory pathways and evaluate the acute and long-term results of transvenous 
cryoablation of septal and superoparaseptal accessory pathways.   
 
Results 
Efficacy 
Acute procedural success was achieved in 26 out of 27 patients (96%). After a mean 
follow-up of 956±511 days, seven patients (27%) had recurrences. Of these seven, 5 
(71%) underwent a second successful cryoablation. No further recurrences were seen 
during 786 ± 484 days in the five patients with a redo procedure. The final success rate 
was 89% (24 out of 27) (Figure 9). 
 
 
 
 
Figure 9. Flow chart of success and recurrence rates of all ablated patients.   
 
 
Total procedure and fluoroscopy time was 163±61 and 30±22 minutes, respectively. 
The procedural characteristics are summarized in Table 2.   
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Table 2 Procedural characteristics 
 
 
  Substrate 
 
  N. 
 
  Cryo    
  success 
 
 
  Procedural  
  time (min) 
  Median (range) 
 
  Fluoroscopy   
  time (min)    
  Median   
  (range) 
 
  Cryo-duration   
  (sec) 
  Median (range) 
 
  Recurrence 
  rate (%) 
 
  All AP 
 
  27 
 
  26 (96%) 
 
  150(70-330) 
 
  21 (6-81) 
 
  450 (240-2464) 
   
  7/26=27% 
   
  Superoparaseptal 
  
  18 
   
  17 
 
  150(80-330) 
 
  20(6-80) 
 
  401 (240-2464) 
 
  4/17(23%) 
   
  Septal 
  
   9 
    
  9 
 
  165(70-220) 
 
  30 (7-81) 
 
  480 (240-1031) 
 
  3/9 (33%) 
 
 
Safety 
No patient showed prolongation of the AH interval during cryomapping. However, 
despite negative cryomapping, two patients, one with a superoparaseptal and the other 
with a septal located AP, developed transient 2nd degree AV block during cryoablation 
that lasted 10 and 25 seconds, respectively. No permanent PR interval prolongation was 
observed at long-term follow-up. 
 
Predictors of recurrence 
Compared to those without mechanical block (5/20, 25%; p = 0.006), recurrence was 
more likely in patients with catheter-induced transient AP block (6/7, 86%) due to 
catheter manipulation. Furthermore, recurrence rate was higher in those who had a 
previous RF ablation attempt (p=0.03). 
 
Conclusion  
Cryoablation is a safe and effective alternative therapy for superoparaseptal and septal 
APs. Procedure-related mechanical AP block predicts a higher recurrence rate. 
 
 
 
Study III 
Safety and efficacy of cryoablation of atrial tachycardia with 
high risk of ablation-related injuries 
 
Aim 
To study the safety and efficacy of cryoablation of atrial tachycardia with high risk of 
ablation-related injuries. The atrial tachycardia foci originated from the para-hisian 
area, the vicinity of the sinus node, and the crista terminalis adjacent to the phrenic 
nerve. 
 
Results  
Efficacy 
Acute procedural success was achieved in 25 of 26 patients (96%). Patients were 
followed up for a mean of 493±258 days. Three patients (12%) had late recurrences. 
Two of these underwent a second successful cryoablation. No further recurrences 
were seen during 383±53 days in the two patients who had a redo procedure, giving a 
total success rate of 92%. 
Total procedure and fluoroscopy time were 197±47 and 26±18 min, respectively. 
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Safety 
No patient showed prolongation of the AH interval during cryomapping. One patient 
had transient AH prolongation during cryoablation. No impairment of SN function 
was observed. 
In a total of 28 procedures, two patients developed phrenic nerve palsy during 
cryoablation of ATs along the lateral right atrium. In one case, the palsy completely 
recovered within one day, and in the one case it fully recovered after five months. 
 
Conclusion  
Cryoablation of high-risk-located AT foci is a safe and effective alternative to RF 
therapy. 
  
 
Study IV 
Cryothermal versus Radiofrequency Ablation as Atrial Flutter 
Therapy: A Randomized Comparison 
 
Aim 
To compare cryoablation and radiofrequency ablation in the treatment of CTI-depenent 
atrial flutter with emphasis on clinical success, safety and procedure-related pain. 
 
Results 
Screening  
 A total of 565 patients with a diagnosis of AFL were screened for the study. Of these 
patients, 153 met all inclusion criteria and were enrolled and assigned to RF (n=75) or 
Cryo (n=78). A great majority of  excluded patients (n=315) did not meet the inclusion 
criteria: No ECG documentation of AFL (n= 49), procedure in general anesthesia (n= 
7); re-do-procedure (n= 60); unable to follow up due to referrals from other counties 
(n= 51); AFL ablation in association with AT, WPW syndrome, AVNRT and His 
ablation (n= 37); predominant atrial fibrillation (n= 98); refused or inability to consent 
(n= 13); and others (n= 97). 
   Two patients in the RF group were excluded from the analysis due to demonstration 
of atrial tachycardia during the index procedure. No patient was lost during follow-up. 
The clinical characteristics are given in Table 3. 
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Table 3 Baseline patient characteristics      
      
   RF Cryo P-value 
 
Patients (n.)   75 78  
Gender, male    59 (79%) 71 (91%) 0.54 
Age (y)    65(34/82) 65(36/82) 0.94 
History of atrial fibrillation  35 (47%) 43 (55%) 0.44 
Cardiovascular disease   37 (49%) 49 (63%) 0.12 
    Arterial hypertension   19 (25%) 31 (39%) 0.08 
    CAD*    5 (7%) 12 (15%) 0.46 
    Congestive Heart failure   9 (12%) 8 (10%) 0.82 
 
Diabetes mellitus   6 (8%) 4 (5%) 0.75 
 
Echo 
   LVEF†    55 (25-55) 55 (15-55) 0.47 
   LVEF < 40%    6 (8%) 9 (11%) 0.72 
   LA-dimension short axis (mm)  40(27-62) 41(30-56) 0.27 
 
Values are given as number, percentage or median (range) 
*CAD, Coronary Artery Disease 
†LVEF, Left Ventricular Ejection Fraction 
 
Efficacy (primary endpoint) 
Acute ablation success was achieved in 71 of 75 patients (95%) in the RF group and in 
72 of 78 patients (92%) in the Cryo group (p=0.58). The success rate after the six-
month follow-up was 92% (69/75) for RF and 86% (67/78) for Cryo; p=0.28, (Figure 
10). 
Patients
enrolled in study
n=153
Cryo-group
n=78
RF-group
n=75
Acute success
n=72
Acute success
n=71
Acute failure
n=6
Acute failure
n=4
Recurrence
n=5 
Recurrence
n=2
6-month success
n=67
6-month  success 
n=69
Assessed for eligibility
n=565
Excluded (n=412) due to not 
meeting inclusion criteria, no ECG 
documentation, procedure in 
general anaesthesia, redo-
procedure, unable to follow up  
(referrals from other countys) ,AFL 
ablation in association with other 
substrate ablation, predominant 
atrial fibrillation, refused or unable 
to consent and others 
.  
Figure 10. Flowchart of acute procedural and six-months follow-up results. 
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Safety (secondary endpoint) 
Pain Perception  
The pain perception was markedly higher for RF than Cryo both regarding the mean 
and peak pain during ablation. Furthermore, there was a significant difference in need 
of intravenous analgesic and sedative medication with lower doses required for Cryo 
(Table 4). 
 
Procedural characteristics  
Procedural time was on average 36 minutes longer in the Cryo group; p < 0.001. The 
median conduction time delay during pacing from proximal CS to the low lateral right 
atrium measured 30 minutes after successful ablation was 140 ms (92-230 ms) in the 
RF group and 141 ms (90-212 ms) in the Cryo group. The corresponding intervals for  
pacing from the low lateral right atrium was 146 ms (100-232 ms) for RF and 144 ms 
(105-200 ms) for Cryo (Table 4). 
  
Table 4 Procedural characteristics      
   RF Cryo P-value 
 
Patients (n.)   75 78  
Fluroscopy time  22±15 18±12  0.06 
Procedural time  116±41 152±54 < 0.001 
Cumulative energy (sec)   72495 214617 < 0.001 
Pain perception (VASpeak)  6.8±2.4 1.8±2.2 < 0.001 
Pain perception (VASaverage) 4.6±2.0 0.7±1.2 < 0.001 
Morphine dose (mg)  11.6±6.0 5.4±3.0 < 0.001 
Diazepam dose (mg)  8.7±5.4 6.9±3.8  0.01  
AAcs pace   143±29 145±25  0.87 
AAlat pace   145±27 146±21  0.79 
 
 
Values are given as number (percentage) or as mean±SD. VAS = visual analog scale 0-10; SR 
= sinus rhythm; AFL = atrial flutter; AF = atrial fibrillation. 
AAcs pace = Conduction time delay during pacing from proximal coronary sinus to the low 
lateral right atrium. AAlat pace = Conduction time delay during pacing from the low lateral right 
atrium to the proximal coronary sinus 
 
Complications 
The only observed clinical complication was a groin hematoma in one patient in the RF 
group. No late complications were observed in any group. 
 
Conclusions   
In this large prospective, randomized, single center study, we show that cryoablation of 
isthmus-dependent atrial flutter is not inferior to RF but with significantly less 
procedure-related pain. 
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GENERAL DISCUSSION 
 
In this thesis, we investigated the safety and efficacy of cryoablation in different 
supraventricular tachyarrhythmias, in order to better understand the capabilities and 
limitations of this novel technology in clinical practice. 
   RF-ablation of most arrhythmic substrates has been shown to be a safe and an 
effective treatment; however, RF energy is associated with several disadvantages, such 
as the operator`s difficulty in predicting the result of the lesion before producing 
permanent damage to the tissue because the electrophysiologic effect appears as the 
lesion is forming. This is particularly important when ablation is performed in the 
vicinity of the AV node, His bundle, coronary arteries, the phrenic nerves, or the sinus 
node, where a significant risk for damage to these structures has been reported. RF 
ablation is also associated with significant pain perception during lesion delivery in 
ablation of CTI- dependent atrial flutter. 
   Cryoenergy has been widely used in the past for open heart surgery ablation of 
arrhythmogenic substrates [31, 36-37, 40]. Recently, this technique has been adapted to 
transvenous catheter ablation. Cryoenergy enables prediction of the effectiveness and 
safety of the lesion. First, a transient and reversible loss of function can be created 
(cryomapping) before additional deep cooling creates an irreversible lesion 
(cryoablation); and second, the catheter tip adheres to the endocardial tissue and 
therefore the risk of dislodgment during the procedure is avoided [23, 33]. Based on 
these considerations, use of cryoenergy should be particularly advantageous when 
ablation is performed in proximity to critical structures. 
 
Clinical Advantages of Cryothermal Energy 
 
The unique biophysical properties of cryothermal energy have a number of advantages, 
that can overcome the important limitations of RF energy. The results presented in this 
thesis show that cryoablation is an effective and safe therapy for several types of 
cardiac arrhythmias such as AVNRT, high risk located AT, perinodal AVRT, and atrial 
flutter. 
 
Efficacy  
Cryoablation in AVNRT 
In Study I, it is shown that acute procedural success in AVNRT with cryoablation was 
achieved in 99% of patients with a recurrence rate of 5.8% during a mean follow-up 
period of 22 months and without any ablation-related long-term complications. Since 
the early 1990s, multiple studies have shown that the efficacy of RF ablation is 
extremely high in the treatment of AVNRT with primary success rates ranging from 
96 to 100% and with late recurrence rates from 1 to 6.9% [1, 78–80]. Since in most 
series the reported results were not based on intention-to-treat analysis, the true 
procedural efficacy of RF-ablation may be slightly lower. Although cryoablation of 
AVNRT has been suggested as a safer alternative to RF energy, there is a large 
variation in the published success rates concerning cryoablation for AVNRT [9, 23, 50, 
81-84]. A possible explanation for the inferior effectiveness in earlier studies is the use 
of a 4-mm tip cryoablation catheter, whereas we exclusively used a 6-mm tip in our 
study [96]. In addition, the high success rate in our report may be related to the 
Hamid Bastani  -  Cryoablation of Cardiac Arrhythmias 
 
 33
approach with systematic cryomapping and ablating only at positions with prompt 
effect on the arrhythmia substrate. 
 
Cryo vs. RF  
In contrast to RF ablation, no junctional rhythm is observed during cryoablation of 
the slow pathway, but the method offers several other parameters to predict the 
potential effectiveness of the ablation site, such as disappearance of dual AV-node 
physiology and non-inducibility of the AVNRT during cryomapping. Sinus rhythm 
usually persists throughout cryoablation of the slow pathway which allows constant 
monitoring of the AV conduction as well as assessment of the presence or absence of 
slow pathway function by programmed stimulation during cryoablation [85]. 
    Because the acute and long-term success rate of RF-ablation in treatment of AVNRT 
is extremely high, it is difficult to conceive an alternative ablation method that is 
significantly more effective. The main reason to consider cryoablation is to improve the 
safety profile without sacrificing the effectiveness. Three randomized prospective trials 
have addressed the question of whether cryoablation of AVNRT is equivalent to RF- 
ablation. In one of these trials [50], no significant difference was found in acute or long-
term efficacy between cryo- and RF-ablation. However, the two other studies [49, 84] 
suggested superior long-term efficacy of RF-ablation compared to cryoablation. Still, as 
one can see in table 5, the effectiveness of both technologies is extremely high both 
regarding acute and long-term success. The combined results of all studies in Table 5 
show a recurrence rate of 7.8% with cryo and 3.4% with RF. 
 
 
Table 5. Comparison of acute success and recurrence rate in published studies using 
Cryoablation versus RF in AVNRT 
__________________________________________________________________ 
                    
   Acute              Recurrences     Persistent 
                                          Patients(n)      Success (%)             (%)         AV Block (n) 
Study CRYO RF CRYO RF CRYO RF CRYO RF 
Kimman et al. (2004)50 30 33 93 91 10 9 0 0 
Zrenner et al. (2004)49 100 100 97 98 8 1 0 1 
Gupta et al. (2006) 86 71 71 85 97 19.8 5.6 0 1 
Collins et al. (2006) 87 57 60 95 100 8 2 0 0 
Avari et al. (2008) 88 38 42 97 95 2 2 0 2 
Chan et al. (2009) 89 80 80 97.5 95 9 1.3 0 2 
Schwagten et al.(2010) 90 144 130 97 95 7.5 6.5 0 2 
Opet et al. (2010) 83 123 149 93 95 10 3 0 1 
Deisenhofer et al. (2010) 84 251 258 96.8 98.4 9.4 4.4 0 3 
Total 894 923 94 96 7.8 3.4 0 12 
 
 
 
Residual dual AV nodal pathway  
The significance of residual dual AV-nodal pathway in predicting late recurrence of 
AVNRT is still inconclusive. Gupta et al. [86] showed a significant higher recurrence 
rate following successful cryotherapy, if an echo beat was still inducible after ablation 
compared with complete slow pathway block, whereas Khairy et al. [91] did not find 
that a residual dual pathway conduction is a predictor for higher recurrence rate. In 
our study that included a large patient population, complete abolishment of the slow 
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pathway was not intentional, but we found a borderline significant relationship 
between recurrence rate and the residual slow pathway conduction. This may suggest 
that the ideal endpoint of cryotherapy in slow–fast AVNRT should be defined as 
complete abolishment of the slow pathway conduction if the circumstances are 
suitable for repeated energy delivery. 
 
Cryoablation in high risk located AVRT  
In study II, acute procedural success with cryoablation in superoparaseptal and septal 
accessory pathways was achieved in 96% (26/27) of patients with a recurrence rate of 
27% (7/26) during a median follow-up period of 33 months and without any ablation 
related long-term complications. Importantly, 71% (5/7) of patients underwent a new 
successful cryoablation, giving a total success rate of 89% after a second cryoablation 
procedure. Thus, acute and long-term results were similar to those described for RF but 
without any complications. 
   The superoparaseptal and septal APs account for only a minority of all APs and 
comprised only 6% of all APs ablated during the study period (five years) in our center. 
This may explain the fact that published data regarding the usefulness of cryoablation 
for the treatment of perinodal APs is still limited [42,92].  
   Previous reports of RF-ablation of superoparaseptal and septal APs have shown 
primary success rates ranging from 71 to 100%, with recurrence rates of 15 to 25% and 
the risk for AV block varying between 0 and 36% [54-55, 93-95]. RF-ablation of 
perinodal APs has an increased risk of inadvertent damage of the normal conduction 
system. This knowledge may influence both the patient’s willingness to undergo an 
ablation procedure and the electrophysiologist’s decision to complete the procedure 
when the risk for complication is perceived high. The use of low-energy RF has been 
recommended to reduce the risk for AV block [56,95], but this technique is associated 
with a higher incidence of recurrences [56, 97-98].   
   Accelerated junctional rhythm during RF energy delivery has been reported in up to 
5% of patients undergoing ablation of septal or superoparaseptal APs [100]. 
Cryomapping/ablation does not result in an accelerated junctional rhythm. Importantly, 
the absence of this rhythm during cryothermal therapy does not mean that the risk for 
damage to the AV node or His bundle is absent. Our data in study II, demonstrate that 
AV block may develop during cryoablation despite negative cryomapping. Therefore, 
our results underline the importance of close monitoring of AV conduction during the 
entire cryoablation procedure. 
 
Catheter-induced AP block 
In study II, catheter-induced trauma resulted in transient mechanical AP block in 11 out 
of 27 (41%) patients. The high incidence of catheter-induced trauma caused by the 
cryocatheter in this study is comparable with previous studies, that used different RF 
catheters [98,100]. Belhassen et al. reported as much as 38% block of AP conduction in 
one or both directions due to catheter manipulation in right superoparaseptal 
(anteroseptal) APs [100]. Haissaguerre and co-workers reported transient mechanical 
block in right superoparaseptal (anteroseptal) APs in 42% [98].  The superficial 
subendocardial location of perinodal APs, particularly the right superoparaseptal APs, 
makes these pathways susceptible to mechanical trauma [98,100]. Our experience shows 
a less favorable late outcome with significantly higher recurrence in patients with 
catheter-induced AP block compared to those without block. This is consistent with 
previous observations, suggesting that cryothermal energy was actually delivered at a 
location different than where the mechanical block was encountered [92]. In contrast to 
the RF catheter, the tip of the cryoablation catheter adheres to the endocardium during 
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energy delivery and does not move, whereas the tip of an RF ablation catheter moves 
across the endocardial surface with each heartbeat, increasing the affected surface area. 
Generally, accessory pathways are very small discrete structures. RF-ablation of such 
structures may be possible even when the catheter tip is not precisely on the target. As 
the cryolesions are more focused due to cryoadherence, it is important that the cryo-
catheter tip is located exactly on the target to achieve success [23]. 
 
Cryoablation in high risk located AT  
Acute procedural success was achieved in 96% (25/26) of patients in study III, using 
cryoablation in AT foci originating from the vicinity of the AV node, the sinus node, 
and the phrenic nerve. The recurrence rate was 12% (3/25) during a mean follow up 
period of 16 months. No further recurrences were seen in 67% (2/3) of patients who 
had a redo-procedure, giving a total success rate of 92%, which is similar to that of 
RF-ablation but without any permanent complications. 
  RF-ablation as a treatment of AT has a primary success rates ranging from 80 to 
100%, with late recurrence rates up to 20% and complication rates up to 12% [55, 
101-106]. Although cryothermal therapy has emerged as an alternative to RF-ablation 
in the treatment of AVNRT [23, 27] and perinodal accessory pathways [42, 92], very 
few data have been published regarding the use of cryoablation for the treatment of 
AT. Data are limited to a small number of patients or case reports [107-108]. The 
effectiveness profile in study III supports the conclusion that cryoablation enables 
effective treatment in high-risk-located AT that otherwise might remain untreated. 
 
Cryoablation in atrial flutter  
In study IV, we conducted the Cryothermal versus Radiofrequency Ablation as Atrial 
Flutter Therapy (CRAFT), which was a non-inferiority and an appropriately powered 
randomized, controlled study to compare systematically cryo with RF for treatment of 
CTI-dependent AFL with emphasis on clinical success, safety, and procedure-related 
pain. The results presented in this study show an acute ablation success of 95% in the 
RF group and of 92% in the cryo group (NS), with achievement of BCB as the 
predefined ablation endpoint. In our study the long-term success after the six-month 
follow-up was 92% for RF and 86% for cryo (NS), results that are consistent with 
recently published studies [66, 68-69, 110-112]. Previous studies of cryoablation in atrial 
flutter have shown acute success rates between 56 and 100% and recurrence rates from 
0 to 20% (Table 6).    
 
Table 6. Comparison of acute success and recurrence rate in published studies using 
cryoablation with 8-mm catheter tip in atrial flutter 
  
Study Patients
(n) 
Acute 
Success 
(%) 
Mean 
Follow-up 
(months) 
Symptom 
Recurrences 
(%) 
Montenero et al. (2005)110 77 96 6 0 
Collins et al.  (2006)69 14 93 15 14 
Kuniss et al. (2006) 113 50 100 1 10 
Wang et al.  (2007) 114 9 100 22 0 
Thornton et al. (2008) 115 32 69 4 0 
Malmborg et al. (2009) 116 20 56 15 20 
Kuniss et al. (2009) 117 90 89 3 11 
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  Kuniss et al. [117] recently found that persistence of BCB in patients treated with 
cryoablation reinvestigated by a new electrophysiological study after three months was 
inferior to that of patients treated with RF. Despite this discrepancy, the acute and long- 
term clinical success in that study was comparable with our results. 
  
Safety 
 
Reversible effects of cryoablation 
The principle drawback to RF-ablation in AVNRT and, perinodal AVRT/AT is the risk 
of irreversible AV block during the procedure, requiring implantation of a permanent 
pacemaker [49,54-55,85,87,89-91,93-95]. This complication is particularly devastating 
in young individuals who may be faced with many decades of pacemaker follow-up, 
generator changes, and potential lead complications. 
   One of the most important characteristics of cryothermal energy is the ability to 
create reversible electrophysiologic effects (cryomapping).   
Dubuc and co-workers showed first in dogs, that complete AV nodal conduction block 
could be created by cooling tissue down to between -20ºC and -30ºC and then 
completely recovered after re-warming. Gross and microscopic examinations could not 
identify any evidence of important tissue injury in the AV junction region. These 
authors further determined that a temperature of approximately -30°C is required to 
interrupt the tissue electrophysiologic properties, that it takes approximately 10 to 20 
seconds of cooling to achieve this temperature, and that re-warming with restoration of 
AV conduction takes up to 20 seconds [20]. The feasibility of cryomapping in humans 
was also later demonstrated by Dubuc and co-workers [22]. They were able to 
demonstrate that reversible AV block could be induced by cooling the tissue of the AV 
node to -30ºC, and that further cooling at the site of successful AV block to -60ºC 
would result in permanent AV node ablation. Finally, several clinical studies have 
validated the concept of cryomapping on larger clinical scale [23, 49-50]. 
   The broad temperature window between reversible electrophysiologic effects and  
irreversible tissue damage, seen with cryothermal energy, is in strong contrast to RF-
related hyperthermal injury [11]. During RF energy delivery, hyperthermal tissue injury 
leading to reversible loss of excitability occurs at a median tissue temperature of 48ºC 
(range 42.7ºC to 51.3ºC), whereas irreversible tissue destruction and irreversible loss of 
excitability typically occurs at tissue temperatures greater than 50ºC [11, 52]. The 
“window of temperature” for RF is, in fact, so narrow that it is meaningless to attempt  
creating reversible lesions. 
   The irreversibility of RF lesions becomes a concern when ablations are performed in 
close proximity to structures critical for normal conduction, e.g., superoparaseptal, 
septal AP, or the slow pathway region of the AV node. This fact results in a small but 
clinically important risk of permanent AV nodal conduction block in conjunction with 
perinodal ablation.  Cryothermal energy in these cases allows the operator to “test” the 
electrophysiologic effects of a lesion before it is made permanent and to abort ablation 
at a site with potentially harmful effects (Figure 11). 
  In Studies I-III, we found that  cryomapping was an extremely useful tool as far as  
perinodal substrates were targeted for ablation. No patient developed permanent AV 
block. These results are in line with other studies of cryothermal ablation [49-50, 84-
85, 87-91] and are in contrast to RF studies reporting AV block in over 1% for fast 
pathway ablation (5,3%) or slow pathway ablation (1-2%) of AVNRT in highly 
experienced centers [1, 12].  
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Figure 11. The reversible effect of cryomapping on the compact AV node. After onset of 
cryomapping at a temperature of -30ºC for 36 seconds, 2:1 AV block occurred. On rewarming, 
the normal AV conduction was immediately resumed. 
 
   The risk of creating permanent AV-block has also been described for ablation of atrial 
tachycardias in the triangle of Koch (12,5%) [53] and for AP ablation in the perinodal 
regions (range 0 to 36%) [54-55, 57, 93-95].   
 
Transient AV block 
In study I, 5% of the patients developed transient second- or third-degree AV block 
either during cryomapping or during cryoablation. A majority of these patients were 
followed long term by ECG Holter monitoring without any indication of delayed AV 
block development and no permanent AV conduction disturbances were seen. 
Therefore, it seems that transient AV block during cryomapping or cryoablation is a 
benign phenomenon with no risk for long-term complications. This is in contrast to 
RF, where even very short RF applications may be sufficient to create immediate or 
late AV block [12, 84]. Of note, studies I-III included several patients in particular 
young ones, who had previously been subjected to an attempt for RF ablation that 
was aborted due to concern of a potential risk for AV block. However, these patients 
subsequently underwent successful cryoablation without any complications. In 
published reports of RF ablation of perinodal substrates, success rates are calculated 
only for those individuals who actually underwent an ablation. These reports do not 
specify how many patients with AVNRT who had undergone an EP study but in 
whom ablation was never attempted due to an estimated high risk of AV block [1,119-
120]. It is Thus likely that a certain number of patients will never be referred for 
curative treatment of their arrhythmia due to the perceived risk of AV-node injury if 
RF ablation is the only treatment option. 
   As a consequence, these “safety-features" of cryoablation make it possible for less 
experienced electrophysiologists to perform AVNRT ablation earlier in their training 
and for low-volume EP laboratories to keep complication rates low. 
   In a recent large series of more than 1300 cryoablation procedures in our center, we 
did not experience any single case of acute permanent AV block and no late AV block in 
the patients with transient AV block after long-term follow-up [121]. Although this 
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study had no control arm with RF-ablation, assuming a low complication rate of AV 
block of 1% during RF procedures, we might have avoided a considerable number of 
pacemaker implants in a relatively young population with a median age of 51 years 
[121]. 
  
Cryoablation of substrates near the phrenic nerve 
RF ablation of arrhythmia substrates  originating in the vicinity of  the phrenic nerve 
carries an increased risk of  irreversible  phrenic nerve  palsy [53,106]. Cryoablation is 
well suited for ablation in the region close to the phrenic nerve.  
   Study III shows high long-term success rate of cryoablation in atrial tachycardia 
originating in the proximity of the phrenic nerve; along the lateral right atrium 
without any sign of persistent phrenic nerve palsy. 
   The premise for cryoablation procedures to avoid phrenic nerve injury involves 
continuous pacing of the phrenic nerve with high output (10mA), from the ablation 
catheter proximal to ablation site. Capture of the right hemidiaphragm should be 
monitored, e.g., by fluoroscopy. At the location of interest, cryomapping at - 30°C is 
perfomed for 30-40 seconds. If this does not lead to cessation of diaphragmatic 
stimulation, cryoablation with a goal temperature of -80ºC for 240 s is applied. 
However, despite negative cryomapping  two patients in study III developed phrenic 
nerve palsy during cryoablation of ATs along the lateral right atrium. In one case, the 
palsy completely recovered within one day, and in a seconds case it fully recovered 
after five months. It is, therefore important to maintain careful monitoring for phrenic 
nerve function during the entire ablation application. In contrast to RF, phrenic nerve 
palsy caused by cryoablation seems to recover more quickly and completely than the 
palsy caused by RF-therapy [122-123]. 
 
Cryoablation of substrate near the sinus node 
 In humans, the sinus node is a spindle-shaped structure, 10- to 20-mm long and 2-to 
3-mm wide and thick. It lies less than 1 mm from the epicardial surface and laterally 
in the RA sulcus terminalis at the junction of the SVC and right atrium. This 
anatomical location may to some extent explain why RF-ablation in this region 
carries an increased risk of complications such as sinus node dysfunction and phrenic 
nerve palsy [106]. 
   In addition, RF-ablation may cause narrowing of the SVC-RA junction [124], which 
may lead to acute or late superior vena cava (SVC) syndrome with irreversible SVC 
stenosis [106, 125-126]. 
   Our results show that cryoablation can be performed with a high long-term success 
rate and a low complication risk in patients with AT in the vicinity of the sinus node 
due to the cryomapping technique as well as cryoadhesion with excellent catheter 
stability.  
 
Improved catheter stability with cryoablation  
Cryoadhesion is an advantageous characteristic of cryothermal therapy which gives an 
increased catheter stability during lesion creation as the heat-extraction process binds 
the catheter tip firmly to the targeted tissue. Clinically, fast temperature decline during 
cooling reflects good contact with the endocardium, whereas inability to quickly 
achieve maximal negative temperatures at the catheter tip indicates poor contact. With 
RF energy delivery, the catheter must be held in place by the operator to ensure 
adequate delivery of power and subsequent tissue heating to the region to obtain the 
desired electrophysiologic effect. Additionally, cardiac motion during RF ablation 
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creates a brushing effect of the catheter on the cardiac tissue, that may make the lesion 
less precise and may increase the risk of undesired damage to adjacent structures, 
particularly near critical conduction tissue.  
   Cryothermal energy is associated with ice ball formation at the tip of the catheter and 
adherence of the catheter to the endocardial surface [20-21]. This effectively eliminates 
the possibility of catheter dislodgement from the desired location once ice ball 
formation has occurred. The increased stability of the cryocatheter may also explain the 
more focal nature of cryothermal energy lesion, which has been investigated in Studies 
I-III. No further fluoroscopy is needed after cryoadhesion occurs. In study IV, we found 
a trend toward shorter fluoroscopy time associated with cryoablation in AFL compared 
to RF, which may be related to the feature of cryoadherence during applications as 
earlier discussed [50]. However, in the same study the procedure time was longer for 
the cryo group as the cryo energy requires longer time for lesion formation point by 
point [46, 127]. 
   Furthermore, the increased catheter stability after ice-ball formation allows 
programmed stimulation to be used during the ablation procedure, to confirm the 
clinical effect of the lesion, without any concern for catheter dislodgement (study I-IV). 
 
  
Decreased thrombogenicity with cryoablation  
Another characteristic of cryothermal energy is the decreased thrombogenicity 
compared with RF [25, 45]. Whereas hyperthermic energy results in coagulation and 
tissue necrosis, [11, 57] cryothermal energy preserves tissue architecture with minimal 
thrombus formation [24-25]. The overall risk of thromboembolic complications related 
to RF therapy ranges from 0.6% to 0.8% [12-14, 58]. However, this risk increases from 
1.8% to 2.0%  when RF is performed in systemic cardiac chambers and can reach as 
high as 2.8% when it is performed for left ventricular VT [12, 14].  
   Although some investigators have suggested that the thromboembolic risk is related 
to the presence of intracardiac catheters rather than delivery of RF energy, there is 
evidence to the contrary. Manolis et al. showed that D-dimer levels increased  two-fold 
after a diagnostic electrophysiologic study (EP study) compared to baseline, but after 
ablation with RF energy D-dimer increased six-fold [70]. Although this study was 
underpowered to demonstrate a difference in clinical events, there is clearly a 
thrombogenic effect associated with the delivery of RF energy.  
   Epstein and colleagues [13] reported an increased thrombous risk associated with 
prolonged RF duration, further supporting the association of RF energy with increased 
thrombogenicity. The use of intravenous heparin protocols and post procedure 
antithrombotic treatment as well as temperature feedback to control RF current delivery 
and monitoring for impedance rise have not been shown to successfully eliminate 
thromboembolic risk [13-14, 59-61].  
   Cryothermal energy lesions cause tissue destruction in an entirely different manner 
and have biophysical properties that make these lesions significantly less 
thrombogenic, or even clinically non-thrombogenic [20, 24-25]. In our studies (I-IV) 
with more than 440 cryoprocedures, we did not find any clinical event related to 
increased thrombogenicity. 
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Minimal risk to vascular structures in cryoablation  
Delivery of RF lesions within venous structures such as the coronary sinus or 
pulmonary vein (PV) is associated with a risk of endoluminal thrombosis, venous 
stenosis, perforation possibly leading to tamponade, or damage to adjacent arterial 
structures [15, 18-19, 58]. Ablation of septal AVRT and typical or atypical AVNRTs 
occasionally require ablation within venous structures, such as the coronary sinus. RF 
ablation of CTI-dependent AFL may injure the right coronary artery. Furthermore, PV 
ablation in AF require the delivery of ablation lesion at the ostia or adjacent to the PVs. 
Delivery of RF lesions is associated with a known risk of PV stenosis [18-19]. 
Cryothermal energy ablation has proved to be less harmful to vascular structures.     
Cryoablation effects on the arteries depend on the extent and depth of cryolesion into 
arterial walls. In cases where conventional transvenous cryocatheters (-80ºC) are placed 
adjacent to the artery, usually no major damage or occlusion of the artery could be 
found. However, coronary spasm has been reported clinically with ablation of  CTI 
dependent AFL [129]. No thrombosis of the arteries has been demonstrated, when  
-80º C freezing with conventional size catheters is applied next to the artery. Intimal 
hyperplasia is a primary and non-specific vessel response to the injury and is frequently 
observed after cryo injury to coronary arteries [130-132].  
   There are no systematic experimental studies with regard to freezing effects on SVC, 
but, at least clinically, no cases of superior vena cava thrombosis or stenosis have been 
reported with cryo. Because vein stenosis after cryoapplication has not been reported in 
smaller diameter veins, such as pulmonary veins, it is highly unlikely that cryoablation 
can cause superior vena caval stenosis [64-65].  
   Catheter ablation within the coronary sinus using cryothermal energy has been 
investigated in animals by Skanes et al. and Yagi et al. [62-63]. Both groups were unable 
to demonstrate thrombus formation or damage to the coronary sinus and concluded that 
this technique is safe and feasible. Bredikis and co-workers used cryoablation to ablate 
posteroseptal and left paraseptal accessory pathways through the coronary sinus, and no 
acute thrombosis was observed in humans [132]. In studies I-IV, no damage to coronary 
vessels was seen. 
  
Less pain perception with cryoablation  
 
RF-therapy is associated with significant perception of pain during lesion delivery, 
compared with similar ablations using cryothermal energy [68]. Afferent pain fibers in 
the myocardium are frozen, instead of being thermally stimulated. Collins and co-
workers showed improved pain score in patients undergoing cryoablation for atrial 
flutter compared with RF ablation [69]. In study IV RF ablation caused significantly 
more pain compared to cryoablation both in terms of average and peak pain perception 
as estimated by the VAS scale. In fact, cryoablation was perceived as nearly pain free 
by the patients.  
   Use of analgesic and sedative medication was compared in this randomized study, 
with significant lower dosages of these medications for cryo. A lower requirement for 
analgesia and less discomfort in patients undergoing cryoablation have previously been 
described and our results reinforce these findings [68, 115]. To reduce patient 
discomfort, some centers offer general anesthesia during RF-ablation of AFL, which 
obviously can be obviated by the use of cryotherapy. Cryoablation may also be useful 
for patients who do not tolerate conscious sedation well.  It can be speculated that pain-
related deep breathing or body movement may increase the risk for complications using 
RF ablation. However, in this study, no complication occurred in any treatment groups. 
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Disadvantages of cryoablation  
Although there are several advantages to using cryoablation in selected cardiac 
arrhythmias, there are also disadvantages. The currently available cryoablation 
catheters are stiffer than the comparable RF catheters. For this reason, there is a greater 
risk of mechanical injury to the arrhythmia substrates using cryoablation. This may 
contribute to the slightly lower success rate using cryoablation. Because the cryo-
catheter is also less flexible than RF catheters, it is more difficult to make more 
advanced maneuvers such as loops. In addition, the current catheters are unidirectional, 
which may require the use of preformed sheaths to aid catheter placement. With 
cryoablation, there may only be a transient effect if the ablation target in a zone of cells 
is only temporarily affected by cooling. This may result in the need for a longer waiting 
period after an ablation. Lastly, the cryoablation catheters are more expensive as they 
are more complicated and must be built by hand.   
 
Summary  
Cryothermal energy is a useful, painless and preferable tool in certain clinical scenarios. 
These may include cases in which the risk of AV block is high (superoparaseptal and 
septal APs, or parahisian AT) or moderate (AVNRT or posteroseptal APs) during RF 
ablation. They may also include cases in which there is a need to ablate in close 
proximity to phrenic nerve, sinus node, venous structures, coronary artery, or CTI. 
There are also clinical scenarios in which RF is the energy source of choice, such as left 
lateral AP. Therefore, cryothermal energy should not be considered as a technology to 
replace RF, but rather as a complementary tool to RF that can treat a broad spectrum of 
clinical arrhythmias with a high level of efficacy and few complications.  
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CONCLUSIONS 
 
 Cryoablation of AVNRT can be performed with a high acute success rate and a 
reasonably low recurrence rate at long-term follow-up without any risk for 
permanent AV block. 
 
 Transient AV block during cryoablation of AVNRT is most likely a benign      
phenomenon. 
 
 Further reduction of the recurrence rate may be achieved with complete 
elimination of slow pathway as endpoint in cryoablation of AVNRT. 
 
 Cryoablation is a safe and effective therapy for superoparaseptal and septal APs. 
 
 Procedure-related mechanical AP block of superoparaseptal and septal APs 
predicts a higher recurrence rate. 
 
 Cryoablation of atrial tachycardia originating from the vicinity of the AV 
node, sinus node, and phrenic nerves is a safe and effective alternative to RF 
therapy. 
 
 Cryoablation of isthmus-dependent atrial flutter is as effective as RF but with 
less procedure-related pain. 
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